CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
具有内在免疫调节作用的高级生物材料用于癌症免疫治疗
英文原题：Advanced Biomaterials with Intrinsic Immunomodulation Effects for Cancer Immunotherapy.
查看英文原题
Advanced Biomaterials with Intrinsic Immunomodulation Effects for Cancer Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近年来，肿瘤免疫治疗基于免疫检查点阻断剂和CAR-T 细胞疗法在肿瘤治疗中取得了显著成功。然而，约70-80%的实体瘤患者由于免疫逃逸而对免疫治疗无应答。近期研究发现，一些生物材料除作为免疫调节药物的载体外，还具有内在的免疫调节作用。此外，这些生物材料还具有易于功能化、修饰和定制等额外优势。本文综述了这些免疫调节生物材料在癌症免疫治疗中的最新进展，以及它们与癌细胞、免疫细胞和免疫抑制性肿瘤微环境的相互作用。最后，讨论了免疫调节生物材料用于临床的机遇与挑战及其在癌症免疫治疗中的未来前景。
展开英文摘要原文
In recent years, tumor immunotherapy has achieved significant success in tumor treatment based on immune checkpoint blockers and chimeric antigen receptor T-cell therapy.
However, about 70-80% of patients with solid tumors do not respond to immunotherapy due to immune evasion. Recent studies found that some biomaterials have intrinsic immunoregulatory effects, except serve as carriers for immunoregulatory drugs.
Moreover, these biomaterials have additional advantages such as easy functionalization, modification, and customization. In this review, the recent advances of these immunoregulatory biomaterials in cancer immunotherapy and their interaction with cancer cells, immune cells, and the immunosuppressive tumor microenvironment are summarized.
Finally, the opportunities and challenges of immunoregulatory biomaterials used in the clinic and the prospect of their future in cancer immunotherapy are discussed.
论文信息
- 作者
- Chen W、Li C、Jiang X
- 单位
- MOE Key Laboratory of High Performance Polymer Materials and Technology and Department of Polymer Science and Engineering, College of Chemistry and Chemical Engineering, Jiangsu Key Laboratory for Nanotechnology, Nanjing University, Nanjing, 210023, P. R. China.China
- 文献类型
- 综述
- 期刊
- Small methods2023 May
- 原文标识
- PubMed 36811240 · DOI 10.1002/smtd.202201404